NRIX - Company ID 0001549595
The table below shows Nurix Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.25M | $7.89M | $44.06M | $18.45M | $12.59M | $12.09M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $84.14M | $86.12M | $78.10M | $69.66M | $55.48M | $48.92M |
Nurix Therapeutics, Inc. reported annual revenue of $83.98M for fiscal year 2025. That is up 54.0% from $54.55M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $31.11M (FY 2019) to $83.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $14.61M |
| $13.16M |
| $14.28M |
| $11.65M |
| $11.72M |
| $11.71M |
| Operating income | -$92.50M | -$91.39M | -$48.32M | -$62.86M | -$54.61M | -$48.54M |
| Income tax | $0.00 | $0.00 | $760.00K | $0.00 | $82.00K | $90.00K |
| Net income | -$87.17M | -$86.42M | -$43.46M | -$56.35M | -$48.96M | -$44.55M |
| EPS (diluted) | -$0.79 | -$1.03 | -$0.52 | -$0.67 | -$0.67 | -$0.71 |